Short versus extended antibiotic treatment with a carbapenem for high-risk febrile neutropenia in hematology patients with Fever of Unknown Origin: a randomized multicenter open-label non-inferiority trial. - SHORT-trial

VU University Medical Center0 个研究点目标入组 240 人开始时间: 2014年11月19日最近更新: 2020年9月7日

适应症

试验速览

暂无简介。

•1.Patients with malignant hematological diseases being treated with cytotoxic chemotherapy or stem cell transplantation;
•2.High-risk neutropenia;
•4.Age 18 years or older;
•5.Written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 220
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•1.Contraindications to use of imipenem-cilastatin or meropenem such as allergy, previous severe side-effects or previous microbiological cultures with carbapenem-resistant microorganism(s).
•2.Corticosteroid use =10 mg per day prednisolone or equivalent for more than 3 consecutive days during the previous 7 days.
•3.Clinically or microbiologically documented infection.
•4.Symptoms of septic shock (systolic blood pressure <90 mm Hg unresponsive to fluid resuscitation and/or oliguria (urine production <500mL/day).
•5.Previous enrollment in this study during the same episode of neutropenia.
•6.Any critical illness for which Intensive Care Unit treatment is required.
•7.Legal incompetency

发起方

VU University Medical Center